9月28日，智通财经记者从白云山获悉，白云山旗下广州广药二期基金股权投资合伙企业（有限合伙， 下称"广药二期基金"）拟出资约7.49亿元人民币，收购Alliance Healthcare Asia Pacific Limited（下 称"AHAPL"）持有的南京医药144,557,431股非限售股份，占总股本的11.04%。交易完成后，广药二期 基金将成为南京医药第二大股东。 在产业协同方面，分销渠道合作上，白云山与南京医药将共同制定市场拓展与渠道共享方案，整合优化 供应链资源和物流配送网络，构建稳定高效的供应链体系；在自有工业品种方面，双方将通过有效机制 推动市场准入和渠道销售，提升产业链协同水平。 在中医药领域，双方将积极支持各自下属中药子公司合作，推进中药工业的转型升级，加快中药生产工 艺和流程的标准化、现代化进程；同时协同建设现代中药材流通体系，建立覆盖种植、加工到销售的全 链条追溯体系。 广药二期基金为白云山出资14.985亿元参与设立的私募股权投资基金，投资方向主要覆盖医药、医疗器 械、医疗服务等生物医药与大健康领域，通过子基金投资或项目直接投资等方式展开布局。（智通财经 李科文） 根据协议，目标 ...

Core Viewpoint - Guangdong Rontai Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor [1]. Company Overview - Rontai Pharmaceutical is a leading provider of out-of-hospital pharmaceutical services in China, focusing on digital marketing and supply chain solutions. It ranks as the fourth largest provider in the out-of-hospital pharmaceutical market and the largest for individual customer marketing and supply chain solutions [3]. - The company has developed a digital precision marketing system and integrates digital business and data platforms with smart logistics infrastructure, offering comprehensive pharmaceutical sales solutions to pharmaceutical companies [3]. Business Model - Rontai Pharmaceutical plays a crucial role in the e-commerce sales channels for pharmaceutical companies, sourcing products from upstream manufacturers and selling them through platforms like JD Health, Alibaba Health, Meituan Medicine, and Dingdang [3]. - The company has established its own retail pharmacy brand, Yikangsi, to directly sell pharmaceutical products to individual customers, simplifying the purchasing process and meeting the growing demand for convenience [4]. Sales Channels - In addition to e-commerce, Rontai Pharmaceutical collaborates with major national and regional chain pharmacies to enhance its sales channels, creating a comprehensive out-of-hospital retail network [6]. - The company has expanded its reach to more grassroots terminals through third-party platforms, further strengthening its penetration in the out-of-hospital market [5]. Financial Performance - For the six months ending June 30, 2022, 2023, 2024, and 2025, the company reported revenues of approximately RMB 2.427 billion, RMB 2.916 billion, RMB 2.875 billion, and RMB 1.540 billion, respectively. The net profits for the same periods were RMB 14.78 million, RMB 45.72 million, RMB 3.74 million, and RMB 17.09 million [6][7].

以下文章来源于LP波谱 ，作者王满华 LP波谱 . 本账号专注LP市场报道。"波浪、谱系"是识别市场的维度，也是定义市场的坐标；此外，波谱（Pop Art）也意为放低意义与史诗的执念，认同商业的日常之美。 将投中网设为"星标⭐"，第一时间收获最新推送 聚焦LP出资、新基金、GP招募，捕捉LP圈一周商业情报。 作者丨王满华 来源丨LP波谱 本周LP圈的焦点属于湖北。 9月20日，湖北大数据集团联合东方财富投资等机构共同发起了湖北省首只数据产业基金，总规模高 达100亿元，首期规模20亿元，将围绕数据产业链上下游展开投资。 当前，数字化浪潮席卷全球，数据已跃升为继土地、劳动力、资本、技术之后的第五大生产要素，成 为推动经济发展的关键力量。作为中部地区的重要省份，湖北也正在着力打造全国数字经济发展高 地。 从目前的发展结果来看，湖北的数字经济已初显成效。2024年，湖北全省数字经济核心产业增加值 达5742.93亿元，是2020年的2.4倍，占GDP的比重预计2025年内将突破10%，综合实力已迈入全国 第一梯队。 而为了进一步强化数据要素统筹运营能力，今年6月，湖北省国资委还联合六家省属企业共同出资50 亿元组建 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、担保情况概述 公司于2024年12月13日召开2024年度第三次临时股东大会，审议通过《关于同意子公司向相关银行申请 综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向相关银行申请综合授信共计13.68 亿元，用于子公司融资业务，具体额度在不超过13.68亿元的金额上限内以银行授信为准，以上综合授 信的金额在一年内以银行授信为准。《关于同意子公司向相关银行申请综合授信额度并为其提供担保的 公告》详见公司指定信息披露媒体《证券时报》《中国证券报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。 二、担保事项进展情况 近日公司与上海浦东发展银行股份有限公司成都分行签署了《最高额保证合同》，为控股子公司四川本 草堂提供连带责任保证，担保的主债权本金余额为最高额人民币2,000万元。 上述担保在已经审议的预计担保额度范围内，公司无需再履行审议程序。 特别提示： 一心堂药业集团股份有限公司(以下简称"公司")本次为控股子公司四川本草堂药业有限 ...

Core Viewpoint - The company, Shenqi Pharmaceutical, is facing regulatory scrutiny due to financial misconduct, which has led to a significant decline in its financial performance in the first half of 2025. Financial Performance - In the first half of 2025, the company reported a revenue of 961 million yuan, a year-on-year decrease of 13.47% [2] - The net profit attributable to shareholders was 32.81 million yuan, down 13.29% year-on-year [2][3] - The net profit after deducting non-recurring gains and losses was 31.98 million yuan, reflecting a decline of 14.74% year-on-year [2][3] - The net cash flow from operating activities decreased by 61.38%, amounting to 47.47 million yuan, primarily due to reduced sales and slower cash collection [4][3] Business Segments - The pharmaceutical manufacturing segment generated 551 million yuan, a decrease of 17.88%, accounting for 57.35% of total revenue [5] - The pharmaceutical commercial segment reported revenue of 409.74 million yuan, down 6.73%, making up 42.65% of total revenue [5] - The decline in the pharmaceutical manufacturing sector is attributed to falling sales revenue within the industry [4] Regulatory Issues - The company received a corrective order from the Shanghai Securities Regulatory Bureau due to financial misconduct involving the misappropriation of sales expenses totaling 44.84 million yuan [1] - Key executives, including the chairman and general manager, received warning letters for failing to fulfill their responsibilities [1] Market Performance - As of September 26, the company's stock price was 6.39 yuan per share, with a market capitalization of 3.413 billion yuan, indicating stagnant performance throughout the year [5]

2025年9月26日，一心堂药业集团股份有限公司发布公告，近日与上海浦东发展银行成都分行签署《最 高额保证合同》，为控股子公司四川本草堂药业有限公司提供2000万元连带责任保证。2024年12月公司 股东大会已审议通过为子公司申请13.68亿元综合授信提供担保的议案，本次担保在预计额度内，无需 再审议。四川本草堂2024年末资产负债率超70%，但信用良好。公司称本次担保必要合理，其他参股股 东按比例反担保，风险可控。本次担保后，公司及控股子公司担保额度达128,227万元，对外担保余额 58,152.01万元，占2024年净资产的7.60%，无逾期担保。 ...

从资金流向上来看，当日医药商业板块主力资金净流出2.82亿元，游资资金净流出5477.97万元，散户资 金净流入3.36亿元。医药商业板块个股资金流向见下表： 证券之星消息，9月26日医药商业板块较上一交易日下跌0.67%，C建发致领跌。当日上证指数报收于 3828.11，下跌0.65%。深证成指报收于13209.0，下跌1.76%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000705 | 浙江農元 | 10.26 | 3.64% | 30.45万 | 3.07亿 | | 002788 | 蜜荷医药 | 8.06 | 0.75% | 3.90万 | 3139.32万 | | 603939 | 益丰药房 | 24.82 | 0.69% | 4.86万 | 1.21亿 | | 000411 | 英特集团 | 11.09 | 0.64% | 3.44万 | 3804.63万 | | 601607 | 上海医药 | 17.94 | 0.17% | 11.57万 | ...

（记者 曾健辉） 每经AI快讯，鹭燕医药9月25日晚间发布公告称，鹭燕医药股份有限公司全资子公司鹭燕嘉文（厦门） 投资发展有限公司于2023年8月成功竞得福建省厦门市翔安区编号2023XG01地块的国有建设用地使用 权，以鹭燕嘉文作为主体建设"鹭燕嘉文总部项目"，并对项目进行开发、建设、运营及管理。为打造医 疗康复、养生调理等医药健康产业生态，鹭燕嘉文拟依托总部项目，增加投资额约为6亿元人民币用于 投资建设具有差异化竞争优势的2家酒店，并以酒店项目为依托，孵化医疗康复、健康养生、养老休 闲、体育、文旅等健康领域业务，延伸健康服务价值链。为便于酒店项目后续的开发建设及管理，鹭燕 嘉文拟以自有资金出资设立2家负责酒店运营管理的全资子公司酒店管理公司，同时引进国际知名酒店 品牌（希尔顿）和经营团队，负责酒店的日常经营管理。2家酒店管理公司注册资本分别为人民币1,000 万元和2,000万元，鹭燕嘉文持股比例均为 100%。 每经头条（nbdtoutiao）——"9·24"一周年，A股总市值破116万亿元！四大变革重塑中国资本市场新生 态 ...

每经AI快讯，鹭燕医药9月25日晚间发布公告称，公司第六届第七次董事会会议于2025年9月22日以现 场方式召开。会议审议了《关于设立全资子公司的议案》等文件。 （记者 张喜威） 每经头条（nbdtoutiao）——"9·24"一周年，A股总市值破116万亿元！四大变革重塑中国资本市场新生 态 ...

Core Viewpoint - Luyuan Pharmaceutical (002788.SZ) announced plans to invest approximately 600 million RMB to develop two hotels, aiming to create a healthcare ecosystem focused on medical rehabilitation and wellness services [1] Investment and Development - The investment will be utilized to build two hotels that will serve as a foundation for expanding into healthcare-related businesses such as rehabilitation, wellness, elderly care, sports, and cultural tourism [1] - Luyuan Jiawen, a subsidiary, will establish two wholly-owned hotel management companies to oversee the operations of the hotels, with registered capital of 10 million RMB and 20 million RMB respectively [1] Strategic Partnerships - The company plans to collaborate with an internationally recognized hotel brand, Hilton, to manage the daily operations of the hotels, enhancing the competitive advantage of the project [1]